C-C motif chemokine 22 predicts postoperative prognosis and adjuvant chemotherapeutic benefits in patients with stage II/III gastric cancer

Wu, Siyu; He, Hongyong; Líu, Hao; Cao, Yifan; Li, Rochen; Zhang, Heng; Li, He; Shen, Zhenbin; Qin, Jing; Xu, Jiejie

doi:10.1080/2162402x.2018.1433517

Cited by 17 publications

(19 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, CCL22 is secreted by M2-like macrophages and cervical cancer cells in cervical cancer. Moreover, many studies proved that cervical cancer cells could induce monocytes into M2 macrophages [18,42] which was consistent with the result in our study to some degree that CCL22 in monocytes could be induced by cervical cancer cells. However, further studies need to be performed to show the effect of cervical cancer cells on M2 macrophages and the regulatory mechanisms of CCL22 needs to be studied in the future.…”

Section: Discussionsupporting

confidence: 92%

“…Another study proved that the levels of serum macrophage-derived CCL22 are associated with glioma risk and survival period [41]. Besides, CCL22 predicts postoperative prognosis in patients with stage II/III gastric cancer [42]. The prognostic value of CCL22 in cervical cancer has, however, not been investigated.…”

Section: Discussionmentioning

confidence: 99%

“…The higher number of CCL22+ cells was significantly associated with lymph node metastasis (p < 0.05), FIGO stages (p < 0.05), therapeutic strategies (p < 0.05), and survival status (p < 0.05). The group with lower number of CCL22 (+) cells had 42…”

Section: The Association Between the Irs Of Ccl22 In CC Cells Infiltmentioning

confidence: 99%

See 2 more Smart Citations

Higher CCL22+ Cell Infiltration is Associated with Poor Prognosis in Cervical Cancer Patients

Wang

Schmoeckel

Kost

et al. 2019

Cancers

View full text Add to dashboard Cite

The chemokine CCL22 recruits regulatory T (T-reg) cells into tumor tissues and is expressed in many human tumors. However, the prognostic role of CCL22 in cervical cancer (CC) has not been determined. This study retrospectively analyzed the clinical significance of the expression of CCL22 and FOXP3 in 230 cervical cancer patients. Immunohistochemical staining analyses of CCL22 and FOXP3 were performed with a tissue microarray. Double immunofluorescence staining, cell coculture, and ELISA were used to determine CCL22 expressing cells and mechanisms. The higher number of infiltrating CCL22+ cells (CCL22 high ) group was associated with lymph node metastasis (p = 0.004), Fédération Internationale de Gynécologie et d'Obstétrique (FIGO) stages (p = 0.010), therapeutic strategies (p = 0.007), and survival status (p = 0.002). The number of infiltrating CCL22+ cells was positively correlated with that of infiltrating FOXP3+ cells (r = 0.210, p = 0.001). The CCL22 high group had a lower overall survival rate (OS), compared to the CCL22 low group (p = 0.001). However, no significant differences in progression free survival (PFS) were noted between the two groups. CCL22 high was an independent predictor of shorter OS (HR, 4.985; p = 0.0001). The OS of the combination group CCL22 high FOXP3 high was significantly lower than that of the combination group CCL22 low FOXP3 low regardless of the FIGO stage and disease subtype. CCL22 high FOXP3 high was an independent indictor of shorter OS (HR, 5.284; p = 0.009). The PFS of group CCL22 high FOXP3 high was significantly lower than that of group CCL22 low FOXP3 low in cervical adenocarcinoma, but CCL22 high FOXP3 high was not an independent indicator (HR, 3.018; p = 0.068). CCL22 was primarily expressed in M2-like macrophages in CC and induced by cervical cancer cells. The findings of our study indicate that cervical cancer patients with elevated CCL22+ infiltrating cells require more aggressive treatment. Moreover, the results provide a basis for subsequent, comprehensive studies to advance the design of immunotherapy for cervical cancer.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Higher CCL22+ Cell Infiltration is Associated with Poor Prognosis in Cervical Cancer Patients

Wang

Schmoeckel

Kost

et al. 2019

Cancers

View full text Add to dashboard Cite

show abstract

“…Of the constructed GC prognostic models, the American Joint Committee on Cancer (AJCC) TNM staging system [20], which has been properly confirmed, is the most broadly utilized prognostic model to forecast outcomes in patients treated with radical operation. Nevertheless, a large weakness of this system is the difficulty in integrating new clinical information, including molecular markers or more elaborate bioinformatics [21].…”

Section: Discussionmentioning

confidence: 99%

“…Patients diagnosed at stage II or stage III were candidates to receive PAC. Collectively, 85.0% (226/266) of patients received 5-FU-based PAC in the stage II/III cohort (at least 1 cycle) [21]. In addition, 20 fresh samples of GC and adjacent noncancerous tissue were obtained between June 1, 2018, and August 1, 2018, at FMUUH and used for Western blot analysis to determine the TBX2 expression levels.…”

Section: Patients and Clinical Databasesmentioning

confidence: 99%

TBX2 Expression predicts Tumor Recurrence and Adjuvant Chemotherapy Benefits in Gastric Cancer Patients following R0 Resection: a proposed approach for risk stratification

Wang

et al. 2020

J. Cancer

View full text Add to dashboard Cite

Aims: TBX2 is related to tumor progression and drug resistance. However, the roles of TBX2 in gastric cancer (GC) remain unclear. Our study aims at investigating the clinical roles of TBX2 in GC. Methods: The protein expression levels of TBX2 in fresh GC tissue (n=20) were investigated with Western blotting analyses. The correlation between TBX2 expression and its prognostic significance was evaluated by immunohistochemical analyses of 401 patients. The survival benefit of postoperative adjuvant chemotherapy (PAC) for patients was evaluated. Results: The expression of TBX2 was increased in GC tissue compared with adjacent paracancerous tissue (p=0.020). Immunohistochemistry demonstrated that TBX2 expression was significantly associated with lymphovascular invasion (p=0.024) and lymph node metastasis (p=0.044). A high level of TBX2 expression was an independent indicator of unfavorable recurrence-free and overall survival (p=0.002 and p=0.033, respectively). The prognostic model incorporating TBX2 expression exhibited greater predictive accuracy than the primary model. More importantly, the benefit of PAC noted in stage II/III GC patients with low TBX2 expression was superior to high TBX2 expression. Conclusion: TBX2 may be not only a useful prognostic marker for GC but also a predictive biomarker of response to PAC in stage II/III GC patients. The current findings warrant further verification.

show abstract

Association of CDX2 and mucin expression with chemotherapeutic benefits in patients with stage II/III gastric cancer

Gao,

Han,

Chen

et al. 2023

Cancer Medicine

View full text Add to dashboard Cite

BackgroundBetter predictors of patients with stage II/III gastric cancer (GC) most likely to benefit from adjuvant chemotherapy are urgently needed. This study aimed to assess the ability of CDX2 and mucin markers to predict prognosis and fluorouracil‐based adjuvant chemotherapy benefits.MethodsCDX2 and mucin protein expressions were examined by immunohistochemistry and compared with survival and adjuvant chemotherapy benefits in a prospective evaluation cohort of 782 stage II/III GC patients. Then, the main findings were validated in an independent validation cohort (n = 386) and an external mRNA sequencing dataset (ACRG cohort, n = 193).ResultsIn the evaluation cohort, CDX2, CD10, MUC2, MUC5AC, and MUC6 expressions were observed in 59.7%, 26.7%, 27.6%, 55.1%, and 57.7% of patients, respectively. However, only the expression of CDX2 was found to be associated with adjuvant chemotherapy benefits. Most importantly, CDX2‐negative patients had a poorer prognosis when treated with surgery only, while the prognosis of CDX2‐negative and CDX2‐positive patients was similar when receiving postoperative adjuvant chemotherapy. Further analysis revealed that patients with CDX2 negative tumors benefited from chemotherapy (5‐year overall survival rates: 60.0% with chemotherapy vs. 23.2% with surgery‐only, p < 0.001), whereas patients with CDX2 positive tumors did not (pinteraction = 0.004). Consistent results were obtained in the validation and ACRG cohorts.ConclusionsNegative expression of CDX2 is an independent risk factor for survival in stage II/III GC, but subsequent adjuvant chemotherapy is able to compensate for this unfavorable effect. Therefore, active chemotherapy is more urgent for patients with negative CDX2 expression than for patients with positive CDX2 expression.

show abstract

C-C motif chemokine 22 predicts postoperative prognosis and adjuvant chemotherapeutic benefits in patients with stage II/III gastric cancer

Cited by 17 publications

References 54 publications

Higher CCL22+ Cell Infiltration is Associated with Poor Prognosis in Cervical Cancer Patients

Higher CCL22+ Cell Infiltration is Associated with Poor Prognosis in Cervical Cancer Patients

TBX2 Expression predicts Tumor Recurrence and Adjuvant Chemotherapy Benefits in Gastric Cancer Patients following R0 Resection: a proposed approach for risk stratification

Association of CDX2 and mucin expression with chemotherapeutic benefits in patients with stage II/III gastric cancer

Contact Info

Product

Resources

About